文献速递炎症性肠病

急性重症溃疡性结肠炎对静脉激素有反应者:降阶梯英夫利西单抗联合硫唑嘌呤与单用硫唑嘌呤的平行开放标签随机对照试验(ACTIVE试验)

Top-down infliximab plus azathioprine versus azathioprine alone in patients with acute severe ulcerative colitis responsive to intravenous steroids: a parallel, open-label randomised controlled trial, the ACTIVE trial.
PubMed 文献 · Gut · 2025-01-17

在法国23个中心开展的多中心平行组开放标签随机对照试验,纳入对静脉激素有反应的急性重症溃疡性结肠炎成人患者64例,随机分入英夫利西单抗联合硫唑嘌呤组或单用硫唑嘌呤组。第52周治疗失败在硫唑嘌呤组为22/27(81.5%),联合组为16/30(53.3%),风险比3.85,95%CI 1.15至12.88,p=0.03。作者认为联合治疗在1年时更有效。

要点

  • 对静脉激素有反应的急性重症溃疡性结肠炎患者中,英夫利西单抗联合硫唑嘌呤较单用硫唑嘌呤减少第52周治疗失败。
  • 第52周治疗失败:硫唑嘌呤组22/27(81.5%)vs 英夫利西单抗联合硫唑嘌呤组16/30(53.3%),风险比3.85,95%CI 1.15至12.88,p=0.03。
  • 严重不良事件29例,包括13例疾病加重和6例严重感染,两组间无差异。

核心结论

  • 对静脉激素有反应的急性重症溃疡性结肠炎患者,英夫利西单抗联合硫唑嘌呤在1年时较单用硫唑嘌呤更有效避免治疗失败。

研究设计与样本

  • 多中心、平行组、开放标签随机对照试验,在法国23个中心开展。
  • 纳入未使用过硫嘌呤和生物制剂的成人急性重症溃疡性结肠炎患者,且对静脉激素有反应。
  • 随机分入英夫利西单抗联合硫唑嘌呤组(英夫利西单抗+硫唑嘌呤,采用7天激素减量方案)或硫唑嘌呤组(硫唑嘌呤联合常规标准化激素减量方案)。
  • 共随机64例患者:英夫利西单抗联合硫唑嘌呤组32例,硫唑嘌呤组32例。
  • 主要复合终点为第52周治疗失败,定义为无无激素临床缓解、无内镜应答、因复发使用禁止的治疗、导致治疗中断的严重不良事件、结肠切除术或死亡。

主要发现

  • 在意向性治疗(ITT)人群中,第52周治疗失败在硫唑嘌呤组为22/27(81.5%),在英夫利西单抗联合硫唑嘌呤组为16/30(53.3%)。
  • 风险比3.85,95%CI 1.15至12.88,p=0.03。
  • 严重不良事件29例,包括13例疾病加重和6例严重感染,两组间无任何差异。
  • 基线Lichtiger评分为13.5±2.0,中位年龄34.5(P25-P75 26.3-50.3)岁,中位C反应蛋白29.0(12.8-96.8)mg/L。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: It is unknown which maintenance therapy is the most effective option for patients admitted for an acute severe ulcerative colitis (ASUC) episode responding to intravenous steroids. METHODS: We conducted a multicentre, parallel-group, open-label randomised controlled trial among 23 French centres in thiopurine and biologics-naïve adults admitted for ASUC responding to intravenous steroids. Eligible patients were randomly assigned to receive infliximab (IFX) and azathioprine (AZA) with a 7-day steroid tapering scheme (IFX+AZA arm) or AZA and conventional standardised steroid tapering regimen (AZA arm). The primary composite endpoint was treatment failure at week 52, defined as the absence of steroid-free clinical remission, the absence of endoscopic response, the use of a prohibited treatment for relapse, severe adverse event leading to treatment interruption, colectomy or death. Multiple imputation for missing data was performed. FINDINGS: Among the 64 patients randomised (Lichtiger score 13.5±2.0; median age of 34.5 (P25-P75 26.3-50.3) years, median C reactive protein of 29.0 (12.8-96.8) mg/L at baseline): 32 were assigned to the IFX+AZA arm and 32 to the AZA arm. In the ITT population, treatment failure at week 52 was observed in 22/27 (81.5%) in the AZA arm and 16/30 (53.3%) in the IFX+AZA arm (risk ratio 3.85, 95% CI (1.15 to 12.88), p=0.03). 29 adverse events were severe, including 13 disease exacerbations, 6 severe infections without any difference between both arms. INTERPRETATION: Combination therapy with IFX+AZA was more effective at 1 year than AZA alone to avoid treatment failure in patients with ASUC responding to intravenous steroids. TRIAL REGISTRATION NUMBER: NCT02425852.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Amiot A, Seksik P, Meyer A, et al. Top-down infliximab plus azathioprine versus azathioprine alone in patients with acute severe ulcerative colitis responsive to intravenous steroids: a parallel, open-label randomised controlled trial, the ACTIVE trial. Gut. 2025. PMID: 39586616. doi:10.1136/gutjnl-2024-333281

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。